Stemline Therapeutics Q3 EPS $(0.34) Beats $(0.45) Estimate, Sales $13.3M Miss $13.64M Estimate

Stemline Therapeutics (NASDAQ:STML) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 53.42 percent increase over losses of $(0.73) per share

Benzinga · 11/07/2019 22:13

Stemline Therapeutics (NASDAQ:STML) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 53.42 percent increase over losses of $(0.73) per share from the same period last year. The company reported quarterly sales of $13.3 million which missed the analyst consensus estimate of $13.64 million by 2.49 percent.